

**PE/Dazzle™ 594 anti-mouse TIGIT (Vstm3)**

**Catalog # / Size:** 1310550 / 100 µg  
1310545 / 25 µg

**Clone:** 1G9


**Isotype:** Mouse IgG1, κ

**Reactivity:** Mouse

**Preparation:** The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions. The solution is free of unconjugated PE/Dazzle™ 594 and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

**Concentration:** 0.2




C57BL/6 Mouse splenocytes were stimulated with Con A and IL-2 for three days, and then stained with CD3 FITC (Clone 145-2C11) and TIGIT (Clone 1G9) PE/Dazzle™ 594 (Top) or mouse IgG1, κ PE/Dazzle™ 594 isotype control (Bottom).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

\* PE/Dazzle™ 594 has a maximum excitation of 566 nm and a maximum emission of 610 nm.



**Application References:** 1. Joller N, *et al.* 2010. *J. Immunol.* 186:1338.

**Description:** T cell immunoreceptor with Ig and ITIM domains (TIGIT), also known as V-set and transmembrane domain-containing protein 3 (Vstm3), is a 26 kD, type I transmembrane protein and member of the CD28 family. TIGIT is expressed on activated T cells, follicular T helper, memory, and regulatory T cells as well as on NK cells. Its binding partners include CD155 (PVR) and CD112 (PVRL2). TIGIT is a negative regulator of NK and T cell activation. Engagement of TIGIT by dendritic cells results in their differentiation into a tolerogenic phenotype, with an increased secretion of IL-10 and a diminished production of IL-12. Mice deficient for TIGIT are more susceptible to autoimmune disease.

**Antigen References:** 1. Levin SD, *et al.* 2011. *Eur. J. Immunol.* 41:902.  
2. Yu X, *et al.* 2009. *Nat. Immunol.* 10:48.

3. Stanietzky N, *et al.* 2009. *P. Natl. Acad. Sci. USA* 106:17858.